Global Vitiligo Pipeline Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Updates, Status and Outlook

News provided by

Aug 04, 2020, 10:45 ET

DUBLIN, Aug. 4, 2020 /PRNewswire/ -- The "Vitiligo Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering.

PIPELINE HIGHLIGHTS

Vitiligo is one of the widely researched conditions during 2020 with 19 companies actively focusing on realizing pipeline's potential. Development of Vitiligo medicines is identified as integral to the strategy of the majority of companies operating in the industry.

Global Vitiligo market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Vitiligo.

Good progress is anticipated during 2020 and 2021 with Vitiligo pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Vitiligo pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.

DRUG DEVELOPMENT PIPELINE OVERVIEW

The Vitiligo pipeline Research Monitor, 2020 report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.

This Vitiligo pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Vitiligo presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Vitiligo pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.

DRUG PROFILES

Vitiligo development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided:

Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
Phase of development
Mechanism of Action
Route of Administration
Companies involved including originator, licensing companies, developer, investors, and others
New molecular entity details
Orphan drug designation and other special status provided by regulators

COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Vitiligo drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Vitiligo. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 19 Vitiligo companies including company overview, key snapshot, contact information, and their strategies on accelerating Vitiligo pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Reasons to Buy

The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
Buyers can identify most promising drug candidates for treatment of Vitiligo
It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
Users can estimate possible delays in the delivery of pipeline or launch of new products
Stay ahead of competition through understanding their pipeline progression, strategies and outlook
The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
Optimize your licensing and technology transfer strategies through identification of prospect partners

Companies Analyzed

2A Pharma AB
Aclaris Therapeutics Inc
Amgen Inc
Arcutis Inc
Arrien Pharmaceuticals LLC
Boston Pharmaceuticals Inc
Bristol-Myers Squibb Co
Castle Creek Biosciences Inc
Clinuvel Pharmaceuticals Ltd
Edesa Biotech Inc
Incyte Corp
Innovision Therapeutics Inc
JN Biosciences LLC
Pfizer Inc
Portola Pharmaceuticals Inc
Radikal Therapeutics Inc
Rheos Medicines Inc
Temprian Therapeutics Inc
Villaris Therapeutics Inc

For more information about this report visit https://www.researchandmarkets.com/r/qg6dgk

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets